Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

Brazilian RCT (n=659) found over 3 months no significant difference in days alive and out of hospital for discontinuing vs continuing ACEIs or ARBs (21.9 vs 22.9 days, OR 0.95, 95%CI 0.90-1.01). There was also no significant difference in death (2.7% vs 2.8%, OR 0.97, 0.38-2.52).

SPS commentary:

Authors highlight these data do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.

Journal of the American Medical Association